Localized Prostate Cancer VL

Adjuvant or Early Salvage Radiotherapy for the Treatment of Localized and Locally Advanced Prostate Cancer - The ARTISTIC Collaborative Journal Club - Christopher Wallis ad Zachary Klaassen

Details
There are a number of trials looking at the role of adjuvant radiotherapy in prostate cancer. It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localized or locally advanced prostate cancer. In this Journal Club, Christopher Wallis, MD, Ph.D., and Zachary Klaassen, MD, MSc discuss the recent publication from th...

Prostate Active Surveillance Study (PASS) - Daniel Lin

Details
The Canary Prostate Active Surveillance Study (PASS) is a multi-center research study for men who have chosen active surveillance to manage their prostate cancer. Canary is the world’s only non-profit focused solely on early cancer detection. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. This i...

How Can We Accelerate Clinical Trial Accrual in Localized Prostate Cancer? - Brian F. Chapin

Details
Brian Chapin, MD, joins Matthew Cooperberg, MD, MPH, FACS, in conversation discussing conceiving and executing large phase III trials focused on the management of localized prostate cancer. Dr. Chapin highlights what it takes to get one of these trials off the ground and what the future of trials looks like for men with localized disease. He specifically highlights the actively recruiting Phase II...

An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener

Details
Historically called Gleason 6, and more recently referred to as Grade Group 1, is a term that started in the 1960s with Don Gleason's original description. It was more universally adopted by the late 1980s, and the Grade Group system was initiated in 2014. In this conversation with Matthew Cooperberg, MD, MPH, FACS, Scott Eggener, MD offers his perspective on the importance of understanding Gleaso...

DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney

Details
Christopher Sweeney, MD, sits down with Alicia Morgans, MD, MPH to discuss “DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Prostate Cancer,” a phase 3, 1100 patient study lead by the ANZUP group which randomizes men with high-risk prostate cancer to darolutamide or standard of care. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical Scho...

The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer - Rana R. Mckay

Details
Rana McKay joins Alicia Morgans to discuss the outcomes of a study investigating randomized patients with high-risk prostate cancer (Gleason ≥4+3, PSA >20, T3 disease, and lymph nodes <20 mm) to either abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) for a total of 6 cycles (each cycle 28 days), followed by radical prostatectomy. A total of...

Active Surveillance for Low-Risk Prostate Cancer - Laurence Klotz and Peter Carroll

Details
Matt Cooperberg hosts a discussion with Peter Carroll and Laurence Klotz examining their roles in the progress of active surveillance for low-risk prostate cancer and how they incorporate this treatment into clinical practice. They discuss the change in the field from over-detection and overtreatment where radiation and surgery were the primary treatment options to the evolution of active surveill...

Study of Baseline PSA Screening of Men (45 years old) - Peter Albers

Details
Peter Albers discusses his study of baseline PSA screening of young men across the nation of Germany. The study consists of 45-year-old men who are randomized in two cohorts, one group gets a PSA immediately and the other cohort has a delay of five years. The initial PSA value determines the patient’s risk-adapted strategy and dictates the schedule of further testing. Dr. Albers states that the tr...

Epidemiologic Outcomes of Prostate Cancer Patients Undergoing Active Surveillance - Sigrid Carlsson

Details
Sigrid Carlsson joins Charles Ryan discussing the epidemiologic outcomes of men in the current era who are facing active surveillance. She reviews the long term data learned from the Memorial Sloan Kettering Cancer Center Experience which mirrors prior reports with low rates of metastasis or cancer-related deaths for patients on active surveillance. They also discuss the migration of pushing the e...

Increasing Rates of Active Surveillance as the Standard of Care in Men with Low Risk Prostate Cancer- Matthew Cooperberg

Details
Matthew Cooperberg discusses active surveillance as the standard of care for men with low-risk prostate cancer as well as data from multiple registries including CaPSURE, MUSIC, AQUA, and SEER, which report increasing rates of active surveillance in men with low-risk disease. He further discusses the factors that may be driving lower uptake of active surveillance in some practices. Biographies: Ma...